摘要
炎症性肠病(IBD)患者肿瘤的患病风险显著高于正常人群,但接受抗肿瘤坏死因子(TNF)制剂治疗是否增加IBD患者发生恶性肿瘤的风险,合并既往恶性肿瘤病史的患者是否仍可继续使用抗TNF制剂,是制定IBD临床决策所面临的重要问题。
The risks of tumors in patients with inflammatory bowel disease(IBD)are significantly higher than that in normal people.It is still obscure whether anti-tumor necrosis factor(anti-TNF)agents increase the risks of malignant tumors in these patients and whether the patients with previous history of malignant tumors could use anti-TNF agents.It becomes an important issue for making clinical decisions.
作者
陈梦诗
曹晓沧
Chen Mengshi;Cao Xiaocang(Department of Gastroenterology,Fujian Provincial Hospital,Fuzhou 350000,China;Department of Gastroenterology,Tianjin Medical University General Hospital,Tianjin 300070,China)
出处
《中华炎性肠病杂志（中英文）》
2020年第2期142-145,共4页
Chinese Journal of Inflammatory Bowel Diseases
基金
天津市科技计划项目支持京津冀协同创新项目基金(19YFSLQY00110)。
